Mutant OPAA Enzymes for Sarin Stereospecific Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current organophosphorus acid anhydrolases, such as wild-type OPAA, exhibit marginal activity against the toxic nerve agent Sarin, and lack stereospecificity, making them ineffective for decontamination and medical countermeasures.
Innovation Solution
Engineering a non-wild-type organophosphorus acid anhydrolase with mutations at positions 212, 342, and 215, specifically substituting Tyrosine with Phenylalanine, Valine with Leucine, and Isoleucine with Aspartic Acid, enhances catalytic efficiency and stereospecificity for Sarin, preferentially degrading the less toxic P(+) enantiomer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type OPAA is used for Sarin degradation, then the enzyme can catalyze hydrolysis of organophosphorus compounds, but the catalytic activity against Sarin is marginal and not practically useful
Solution Approach 1:
The patent applies parameter changes by modifying amino acid residues at positions 212, 342, and 215 of the OPAA enzyme sequence. These specific parameter changes in the enzyme structure result in a mutant enzyme with significantly enhanced catalytic activity against Sarin, transforming it from marginally active to practically useful for decontamination applications.
2Adaptability or versatility
If wild-type OPAA is used for Sarin degradation, then the enzyme can process racemic mixtures, but it lacks stereospecificity and cannot preferentially degrade the less toxic P(+) enantiomer
Solution Approach 1:
The patent applies local quality by introducing specific amino acid substitutions at positions 212 (Tyrosine to Phenylalanine), 342 (Valine to Leucine), and 215 (Isoleucine to Aspartic Acid). These localized changes in the enzyme's active site create stereospecificity, enabling the mutant enzyme to preferentially recognize and degrade the less toxic P(+) enantiomer of Sarin while maintaining overall catalytic efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered enzyme achieves similar or higher catalytic activity against Sarin compared to wild-type OPAA, with enhanced stereospecificity, allowing for effective enrichment and decontamination of the P(+) enantiomer, improving detoxification efficiency.
Implementation Method 1
a class of enzymes known as organophosphorus acid ('OPA') anhydrolases ('OPAA') (EC 3.1.8.2) can catalyze the hydrolysis of a variety of OP compounds
Implementation Method 2
the engineered enzyme achieves similar or higher catalytic activity against Sarin compared to wild-type OPAA
Data Source
AI summary
Disclosed herein are non-wild-type organophosphorus acid anhydrolases having three site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as((RS)-Propan-2-yl methylphosphonofluoridate)(Sarin) and other organophosphorus compounds. Also provided are organophosphorus acid anhydrolase mutants capable of degrading Sarin with distinct selective stereospecificity preferences differing from the wild-type organophosphorus acid anhydrolase